articleThe LancetSep 19, 2009Closed access

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

NKNoriyuki KatsumataMYMakoto YasudaFTFumiaki TakahashiSISeiji IsonishiTJToshiko Jobo

National Cancer Center Hospital East · Jikei University School of Medicine · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

733
total citations
FWCI
57.34
Percentile
100%
References
26
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Medicine
  • Carboplatin
  • Regimen
  • Hazard ratio
  • Ovarian cancer
  • Internal medicine
  • Clinical endpoint
  • Paclitaxel
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding